Genome, Environment, Microbiome and Metabolome in Autism (GEMMA)- Research Opportunity
An event every month that begins at 12:00 am on day 3 of the month, repeating until September 30, 2021
GEMMA is an incredibly ambitious, one-of-a-kind multicenter study that seeks to identify potential biomarkers predictive of autism development and ultimately predict, prevent and treat autism spectrum disorders. Specifically, the study is aimed at understanding the role that our genes, gut microbiome, and environmental factors play in the development of autism. The goal is to recruit a total of 600 infants in the US, Italy and Ireland. Infants in the womb or less than 6 months of age who have a first-degree relative (sibling) with autism are eligible to participate in the study, and here at Massachusetts General Hospital we are currently recruiting from all over the country.
We will be collecting blood, stool, saliva and urine samples from participating families (infant, sibling(s) with autism and parents). As we enroll and follow these infants through their early life, we hope to identify and stratify vulnerable patients by exploring the relationship between the gut microbiome and autism development, which, optimistically, will translate into interventions preventing the onset of autism and related comorbidities.
Participants have a first-hand, active role in ground-breaking science and around-the-clock access to the GEMMA study team, comprised of experts in the field of autism. Participants are also welcomed into a community of like-minded families, as we all work collectively to improve our knowledge of autism.